Sustained low-efficiency dialysis for renal replacement therapy in the ICU: a cost-benefit analysis of the years 2006 to 2010

Abstract

Sustained low-efficiency dialysis (SLED) as primary renal replacement therapy in acute renal failure is still not widely used compared to continuous venovenous hemodiafiltration (CVVHDF), despite possible economical advantages. Based on one key paper [1] we use SLED as primary renal replacement therapy. However, since medical and economical data with SLED are scarce, we evaluated costs and outcome in a 5-year retrospective study on our ICU.